0000939767-18-000071.txt : 20180504
0000939767-18-000071.hdr.sgml : 20180504
20180504190652
ACCESSION NUMBER: 0000939767-18-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180503
FILED AS OF DATE: 20180504
DATE AS OF CHANGE: 20180504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwab Gisela
CENTRAL INDEX KEY: 0001213140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 18809420
MAIL ADDRESS:
STREET 1: 6701 KAISER DRIVE
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER NAME:
FORMER CONFORMED NAME: SCHWAB GISELA MD
DATE OF NAME CHANGE: 20030107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0102
BUSINESS ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_152547516260192.xml
FORM 4
X0306
4
2018-05-03
0
0000939767
EXELIXIS, INC.
EXEL
0001213140
Schwab Gisela
C/O EXELIXIS, INC.
210 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Pres Prod Dev & Med Aff & CMO
Common Stock
2018-05-03
4
M
0
22500
5.50
A
300788
D
Common Stock
2018-05-03
4
S
0
7800
22.36
D
292988
D
Common Stock
2018-05-03
4
S
0
14700
23.47
D
278288
D
Common Stock
14505
I
By 401(k)
Option (right to buy)
5.5
2018-05-03
4
M
0
22500
0
D
2012-09-28
2018-09-27
Common Stock
22500.0
90000
D
Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,008 shares of common stock acquired on April 30, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.95 to $22.90. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.98 to $23.75. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 2, 2018.
The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2018-05-04